Health care manufacturing win for Melbourne

Media release

28 February 2014

The decision by Fresenius Kabi, a German healthcare company, to build a $47 million state-of-the-art pharmaceutical manufacturing facility in Melbourne has been welcomed by the Minister for Trade and Investment, Andrew Robb.

Fresenius Kabi has decided to expand its existing operations in Australia with the greenfield facility that will create 120 highly-skilled jobs.

"This is very welcome news for Victoria's high end manufacturing sector and recognises Australia's strong research credentials and commitment to world-class innovation, which are among our country's great strengths," Mr Robb said.

The facility will produce innovative infusion therapies, irrigation solutions, intravenous generic drugs and compounded oncology products.

Ms Zita Peach, Managing Director for Australia and New Zealand and Executive Vice President South Asia Pacific of Fresenius Kabi, said; "It is an endorsement of our skills base, our expertise in medical products and device manufacturing, and our reputation in the Asia-Pacific as a high quality health care supplier and exporter."

Austrade worked in partnership with the Victorian Government to secure the project, which is aligned with the Australian Government's priority to attract foreign direct investment in Advanced Manufacturing, Services and Technologies.

"This is one of five national investment priorities that were agreed at a recent meeting I hosted with my state and territory ministerial colleagues in trade and investment," Mr Robb said.

"Working closely with the states and territories, the Australian Government will continue to promote Australia's strengths in industries in which we have a strong competitive advantage, including where we are able to build on Australia's manufacturing pedigree in market niches and create high value, sustainable jobs for Australians."

About Fresenius

Fresenius Kabi is a global health care company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. The company's products and services are used to help care for critically and chronically ill patients. They comprise a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the medical devices for administering these products. Within transfusion technologies, Fresenius Kabi offers products for whole blood and blood components collection and processing as well as for transfusion medicine and cell therapies.

Fresenius Kabi employs around 30,000 people worldwide. In 2012 the company reported sales of more than €4.5 billion. Fresenius Kabi AG is a wholly owned subsidiary of the Fresenius SE & Co. KGaA health care group.

Media enquiries

  • Trade Minister's Office: (02) 6277 7420
  • DFAT Media Liaison: (02) 6261 1555